Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection. Issue 2 (February 2014)

• Record Type: Journal Article
• Authors: Leuthner, Kimberly D; Yuen, Angela; Mao, Yu; Rahbar, Aryan
• Is Part Of: Expert review of anti-infective therapy. Volume 13:Issue 2(2015)
• Page Start: 149
• Page End: 159
• Publication Date: 2014-02
• Subjects: Anti-infective agents -- Research -- Periodicals; 616.90461
• DOI: 10.1586/14787210.2015.995633
• Languages: English
• ISSNs: 1478-7210

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>In the era of increasing antibiotic resistance, development of new agents that could provide therapeutic options for difficult to treat pathogens is vital. Dalbavancin is a new lipoglycopeptide recently approved by the US FDA for the treatment of acute bacterial skin and skin structure infections. A derivative of the older glycopeptide class, chemical structure alterations resulted in a molecule with a similar mechanism of action, however, with a comparatively increased activity as reflected by organism MICs. These modifications also resulted in an antibiotic with distinctive properties that allow for once-weekly dosing in the treatment of Gram-positive pathogens, including methicillin-resistant <italic>Staphylococcus aureus</italic> and drug resistant <italic>Streptococcus</italic> spp. As the first of these long acting compounds, understanding the pharmacokinetic and pharmacodynamic properties of agents like dalbavancin is essential for determining a place in therapy.</p> </abstract>